Western blotting showed a dose- and time-dependent decrease in HSP90 expression in breast cancer cells in all studies, and the induction of HSP70 by withanolides was confirmed by the knockdown of HSP70 using shRNA, enhancing the cytotoxicity in MBA-MB-231 cells [44]. The gene discussed is HSP90AB1; the disease is breast carcinoma.